{"id":"7006b96b-a7ee-48b1-afe9-7713e22ed10f","url":"content/7006b96b-a7ee-48b1-afe9-7713e22ed10f","title":"What does the treatment involve?","outline":"/publication/75bfaa02-cc71-4a79-a7dd-dbc47541edea/outline","content":{"mime":"application/xml","data":"<?xml version=\"1.0\" encoding=\"UTF-8\"?>\n<!-- content-type_s: --><!-- Generated by cjs2htmlbase.xsl--><div data-ot-plugin=\"com.congility.html\" lang=\"en\" role=\"main\" xmlns:astX=\"http://www.astoriasoftware.com/translation\"><div class=\"topic service-user-information commentable-section\" data-annot-id=\"topic.dita_1508d778-3082-42b4-b4ae-c50d2104b864\" id=\"topic.dita_1508d778-3082-42b4-b4ae-c50d2104b864\"><article aria-labelledby=\"ariaid-title1\" role=\"article\">\n  \n  \n  <div class=\"body service-user-information-body\">\n    <p class=\"p\">Adjuvant trastuzumab and chemotherapy is standard care for HER2-positive breast cancer. Trastuzumab can also be given in addition to surgery and radiotherapy. </p>\n    <p class=\"p\">Trastuzumab is given by intravenous infusion or subcutaneous injection every 3 weeks for 1 year. </p>\n  </div>\n</article></div></div>"},"metadata":{},"solr":{"custom":{},"doc":{"href_s":"SD00835159","url_s":"content/7006b96b-a7ee-48b1-afe9-7713e22ed10f","title_s":"What does the treatment involve?","nextTopic_s":"3b204106-8abd-4b8d-8536-8e8788e9b7aa","prevTopic_s":"a384e02b-54b2-4c76-81b6-2af89dfa611f"},"nice":{"nice_infotype_s":"service-user-information","nice_guideline-id_s":"","nice_content-id_s":"","nice_content-type_s":""}},"contentObject":{"publicationuuid":"75bfaa02-cc71-4a79-a7dd-dbc47541edea","contentuuid":"7006b96b-a7ee-48b1-afe9-7713e22ed10f","contentjoinuuid":"1674f744-e7ef-42a5-a7b9-28b9bcc0958f","contentjoinuuids":["1674f744-e7ef-42a5-a7b9-28b9bcc0958f","b6411394-b182-48a0-932b-feab3de553ac"],"publicationjoinuuid":"356cbf6a-a380-418a-9856-781ae39f6dca"}}